This legislation is the sequel to the 21st Century Cures Act, which was signed into law in 2016 and focused on streamlining the drug and device approval process, increasing biomedical research and precision medicine, and developing targeted drugs for rare diseases.
Cures 2.0 aims to continue this effort by including policy changes to accelerate the discovery, development and delivery of 21st century cures, and advance the development of and access to innovative treatments.
Here are several important provisions included in Cures 2.0 that would impact GI:
Increases access to telehealth services for Medicare and Medicaid patients, including those covered under CHIP. This policy would:
- Remove Medicare’s geographic and originating site restrictions.
- Allow the Secretary of HHS to permanently expand the types of health care providers that can offer telehealth services and the types of services that can be reimbursed under Medicare.
Encourages innovative antimicrobial drug development.
Transforms how Medicare covers innovative new treatments and technologies to make those new discoveries available to patients sooner.
Expands access to federal health plan claims data for research purposes to improve quality and cost-efficiency by linking the data with clinical data in registries.
Requires more diversity in clinical trials to ensure any new drugs and treatments approved for use in the U.S. are both safe and effective for a greater — and more representative — portion of the population.
Authorizes $6.5 billion to create ARPA-H within NIH.
Provides patients more information about the illness they face and the treatment options available to them to make them a more integral part of the decision-making process.
Requires studies into the implications of long COVID, including health disparities.
Includes the RISE Act, which provides $25 billion to federally backed researchers impacted by the COVID-19 pandemic.